NASDAQ:IBRX.O 20 January 2026 - 17 May 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio Inc. shares will react Monday to news of a fresh bladder-cancer supply agreement. The company said Saturday it now has exclusive U.S. rights to develop, import and sell the Tokyo-172 BCG strain from Japan BCG Laboratory.

17 May 2026

NASDAQ:IBRX.O·Pharmaceutical Industry·Stock Market

ImmunityBio stock jumps before the open after FDA outlines next step for ANKTIVA filing

ImmunityBio shares rose about 27% to $7 in premarket trading on Tuesday, with about 4.1 million shares changing hands, after the company said it had made progress with the U.S. Food and Drug Administration on a path to revive a label-expansion push for its bladder cancer treatment ANKTIVA.

20 January 2026

Biotechnology·NASDAQ:IBRX.O·Stock Market

Go toTop